June 4th 2024
A promising new treatment option has emerged for patients with a specific type of gastrointestinal stromal tumor that has become resistant to standard therapy.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Diaz Discusses Phase III Trial of Pembrolizumab in Frontline MSI-H Colorectal Cancer
September 27th 2017In the phase III KEYNOTE-177 trial, investigators are hoping to show that frontline treatment with the PD-1 inhibitor pembrolizumab (Keytruda) can improve progression-free survival compared with standard-of-care chemotherapy in patients with mismatch repair-deficient or microsatellite instability-high colorectal cancer.
Read More
Expert Discusses Study Exploring Prognostic, Predictive Value of Tumor Location in CRC
September 26th 2017Investigators aimed to evaluate the prognostic value of primary tumor location in patients with fully resected colon cancer, as well as its relationship to microsatellite instability-high (MSI-H), <em>RAS</em>, and <em>BRAF</em> mutational status, in a study presented at this year's World Congress on Gastrointestinal Cancer.
Read More
Improving Outcomes in Pancreatic Cancer With Perioperative mFOLFIRINOX
September 26th 2017Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the need for an ongoing study exploring mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.
Watch
Pembrolizumab Receives FDA Approval for PD-L1+ Gastric Cancer
September 23rd 2017Based on findings from the phase II KEYNOTE-059 study, pembrolizumab has been granted FDA approval for the treatment of patients with PD-L1–positive recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have received 2 or more lines of chemotherapy, including fluoropyrimidine- and platinum-containing chemotherapy, and, if appropriate, HER2/neu-targeted therapy.
Read More
Pisters Selected as Next MD Anderson Cancer Center President
September 22nd 2017Peter W. T. Pisters, MD, MHCM, has been chosen as the next president of The University of Texas MD Anderson Cancer Center. Pisters has served as president and CEO of University of Health Network (UHN) of Toronto since 2015.
Read More
BLU-554 Demonstrates Improved Response Rates in HCC
September 21st 2017While currently-approved treatments for HCC are typically associated with responses rates of 10% or less, findings presented at the 11th Annual Conference of the ILCA, BLU-554, a potent and highly selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), induced an overall response rate of 16% (95% CI, 6-31) in patients with FGF 19 IHC-positive HCC.
Read More
Lenvatinib Continues to be Noninferior to Sorafenib in Liver Cancer, Updated Results Show
September 21st 2017In updated phase III results, lenvatinib continued to be noninferior in overall survival compared with sorafenib for patients with unresectable hepatocellular carcinoma, and achieved significant improvements in progression-free survival, time to progression, and objective response rate compared with sorafenib.
Read More
ABP-215, First Biosimilar for Cancer Treatment, Approved by FDA
September 15th 2017Today, ABP-215, a biosimilar for bevacizumab developed by Amgen and Allergan, received FDA approval for the treatment of several different cancer types, making it the first biosimilar approved for the treatment of cancer.
Read More
FDA Extends Decision Deadline on Trastuzumab Biosimilar MYL-1401O
September 1st 2017The decision deadline on a biologics license application (BLA) for MYL-1401O, a trastuzumab (Herceptin) biosimilar co-developed by Mylan and Biocon, has been extended by 3 months, the FDA has announced. Under the new timeframe, a final decision is expected on or before December 3, 2017.
Read More
Expert Speaks on Importance of Genetic Testing in GI Cancers
August 24th 2017Antonia R. Sepulveda, MD, PhD, discusses the importance and utility of genetic testing in GI cancers, as well as noteworthy developments in microsatellite instability, <em>BRAF</em>, and <em>KRAS </em>testing in colorectal cancer.
Read More
Recurrence-Free Survival in GIST at 90% With Long-Term Imatinib
August 22nd 2017Patients with intermediate- or high-risk gastrointestinal stromal tumors were less likely to experience recurrence after 5 years of treatment with imatinib, according to results from the phase II PERSIST-5 trial.
Read More
Exploring the Decreasing Incidence of Colon Cancer in Those Over the Age of 50
August 18th 2017Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine and New York-Presbyterian Hospital, discusses the decreasing incidence of colon cancer diagnosis in those over the age of 50.
Watch
Novel Bispecific Antibody Shows Promising Efficacy in Heavily Pretreated mCRC
August 18th 2017In patients with heavily-pretreated microsatellite stable metastatic colorectal cancer (mCRC), treatment with CEA-TCB, an investigational CEA/CD3 bispecific antibody, showed a favorable safety profile and promising efficacy, with enhanced efficacy when combined with the PD-L1 inhibitor atezolizumab.
Read More
Expert Discusses Evaluation of Surgical Intervention in Metastatic CRC
August 17th 2017Dominik P. Modest, MD, discusses a retrospective, central evaluation of the FIRE-3 study to determine surgical treatment options, which explored the number of patients with metastatic colorectal cancer who had resectable disease during systemic first-line therapy.
Read More
Trent Shares Treatment Considerations in 2 GIST Patient Cases
August 4th 2017Jonathan C. Trent, MD, PhD, recently discussed the treatment considerations he makes when treating patients with gastrointestinal stromal tumors (GIST). Trent discussed his treatment decisions based on 2 case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives dinner.
Read More
Nivolumab Approved by FDA for MSI-H or dMMR Colorectal Cancer
August 1st 2017Nivolumab (Opdivo) has been granted an accelerated approval by the FDA for the treatment of adult and pediatric patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
Read More
Simeone Leads New NYU Pancreatic Cancer Center
August 1st 2017Diane M. Simeone, MD, is stepping up to lead the new Pancreatic Cancer Center at NYU Langone. She has been a member of NYU Langone since March 2017, and will continue in her role as associate director of translational research at the Perlmutter Cancer Center.
Read More
Lutathera Receives EMA Panel's Support for Approval for GEP-NETs
July 24th 2017Lutathera (lutetium [<sup>177</sup>Lu] oxodotreotide) has been recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of patients with unresectable or metastatic, progressive, well-differentiated (grade 1 and grade 2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Read More